You are here

Genasense Trial in Advanced Multiple Myeloma Does Not Meet Primary End Point

BERKELEY HEIGHTS, N.J., Nov. 26 /PRNewswire-FirstCall/ -- Genta Incorporated announced today that the Company's randomized Phase 3 clinical trial of Genasense® (oblimersen sodium) Injection in patients with advanced multiple myeloma did not meet its primary end-point. The trial had been designed to evaluate whether the addition of Genasense to standard therapy with high-dose dexamethasone could increase the time to development of progressive disease in patients who previously had received extensive therapy. Further details of the trial results will be presented on Saturday, December 4, 2004 at the annual meeting of the American Society of Hematology (ASH) in San Diego, CA.

"The strength of the preclinical data, combined with results from two preliminary, non-randomized trials, provided a strong rationale for this Phase 3 study," said Dr. Raymond P. Warrell, Jr., Genta's Chairman and Chief Executive Officer. "While we are disappointed with these results, we plan to analyze this trial in considerably more detail before making decisions regarding the Genasense program in myeloma."

About Multiple Myeloma

Multiple myeloma is a cancer of white blood cells that are called plasma cells. In myeloma, these cells, which normally produce infection-fighting antibodies, become mutated and then multiply uncontrollably. This proliferation crowds out normal red and white blood cells, leading to infections, bleeding and anemia. The illness also decreases production of normal antibodies and causes widespread destruction of bone that produces fractures, pain and progressive disability. More information about the disease is available through the Multiple Myeloma Research Foundation: http://www.multiplemyeloma.org/

About Genasense

Genasense inhibits production of Bcl-2, a protein made by cancer cells that is thought to block chemotherapy-induced apoptosis (programmed cell death). By reducing the amount of Bcl-2 in cancer cells, Genasense may enhance the effectiveness of current anticancer treatment. Genta is pursuing a broad clinical development program with Genasense.

Source: Genta

Recent Headlines

Triggers the Body’s Own Natural Blood Flow Regulation
Inrebic Reduces Symptoms by 50% in Some Patients
Novel Catheter-based Technology for Treating Acute Ischemic Stroke
Decision supported by data from more than 4,000 patients
Statistically Significant Improvement in Excessive Daytime Sleepiness
Researcher Made Himself Guinea Pig to Test the Drug
Treatment Shorter, Less Complicated Than Typical Regimen
Zip Device Faster to Apply, Minimizes Scarring